Translational PK/PD Modeling of Tumor Growth Inhibition and Target Inhibition to Support Dose Range Selection of the LMP7 Inhibitor M3258 in Relapsed/Refractory Multiple Myeloma-Reference-Cited by-同舟云学术

Translational PK/PD Modeling of Tumor Growth Inhibition and Target Inhibition to Support Dose Range Selection of the LMP7 Inhibitor M3258 in Relapsed/Refractory Multiple Myeloma

Published:2022-10-23 Issue:1 Volume:384 Page:163-172
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

Lignet Floriane^ORCID,Esdar Christina,Walter-Bausch Gina,Friese-Hamim Manja,Stinchi Sofia,Drouin Elise,El Bawab Samer,Becker Andreas D.,Gimmi Claude,Sanderson Michael P.,Rohdich Felix

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference34 articles.

1. Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma

2. HLA and proteasome expression body map;Boegel;BMC Med Genomics,2018

3. Model-Based Prediction of Phase III Overall Survival in Colorectal Cancer on the Basis of Phase II Tumor Dynamics

4. Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma;Ettari;Pharmacol Ther,2018

5. A humanized yeast proteasome identifies unique binding modes of inhibitors for the immunosubunit β5i

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preclinical Pharmacokinetics in Tumors and Normal Tissues of the Antigene PNA Oligonucleotide MYCN-Inhibitor BGA002;Nucleic Acid Therapeutics;2024-08-01

2. Comparison of Tumor Binding Across Tumor Types and Cell Lines to Support Free Drug Considerations for Oncology Drug Discovery;Journal of Pharmaceutical Sciences;2023-11

3. Ubiquitin–proteasome system as a target for anticancer treatment—an update;Archives of Pharmacal Research;2023-07